Macquarie Group’s Editas Medicine EDIT Stock Holding History

Macquarie Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,190	Closed	-$24K	–	1863
2022 Q3	$24K	Sell	1,190 -767	-39%	-$12K	﹤0.01%	2148
2022 Q2	$23K	Hold	1,957	–	–	﹤0.01%	2264
2022 Q1	$37	Hold	1,957	–	–	﹤0.01%	2241
2021 Q4	$52K	Hold	1,957	–	–	﹤0.01%	2148
2021 Q3	$80K	Hold	1,957	–	–	﹤0.01%	2057
2021 Q2	$111K	Buy	1,957 +322	+20%	+$11.9K	﹤0.01%	1941
2021 Q1	$69K	Sell	1,635 -502	-23%	-$28.6K	﹤0.01%	1993
2020 Q4	$150K	Hold	2,137	–	–	﹤0.01%	1762
2020 Q3	$60K	Hold	2,137	–	–	﹤0.01%	1913
2020 Q2	$63K	Buy	+2,137	New	+$55.8K	﹤0.01%	1873
2018 Q3	–	Sell	-400	Closed	-$14K	–	2181
2018 Q2	$14K	Buy	+400	New	+$14.2K	﹤0.01%	2104
2018 Q1	–	Sell	-2,600	Closed	-$80K	–	2216
2017 Q4	$80K	Buy	+2,600	New	+$65.5K	﹤0.01%	1932

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Macquarie Group's EDIT Position: Q4 2022 in Review

Macquarie Group sold out of Editas Medicine (EDIT) in Q4 2022, closing a stake of 1,190 shares — an estimated $24K sold.

Macquarie Group first reported a position in EDIT in Q4 2017 and held it in 12 quarters. The position peaked at $150K in Q4 2020. 250 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

Macquarie Group reported no remaining Editas Medicine position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 1,190 Editas Medicine shares in Q4 2022, an estimated $24K.
Macquarie Group first reported a position in Editas Medicine in Q4 2017 and held it in 12 quarters.
Macquarie Group's Editas Medicine position peaked at $150K in Q4 2020.
250 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.